Lantern Pharma Reports Complete Response in Phase 1 LP-284 Trial for Aggressive Lymphoma

Lantern Pharma presented clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma Congress showing a confirmed complete metabolic response in a 41-year-old patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma. The patient had failed four prior treatment regimens, including CAR-T and bispecific antibody therapies, making this response particularly significant for addressing treatment-resistant cases. The complete metabolic response was achieved after just two 28-day cycles of LP-284 treatment, supporting the drug's synthetic lethal mechanism and its potential to fill a critical post-immunotherapy treatment gap in hematologic malignancies.

CEO Panna Sharma emphasized that these results validate the company's AI-driven approach to drug development and highlight LP-284's dual potential as both a monotherapy and in combination with FDA-approved agents such as rituximab. The favorable early safety profile observed in the trial adds to the drug's promising clinical profile, particularly important for patients who have exhausted multiple treatment options. Lantern noted that LP-284 has received multiple FDA Orphan Drug Designations and maintains strong intellectual property protection through 2039, providing substantial market exclusivity if the drug progresses through development successfully.

The company's RADR AI platform, which leverages over 200 billion oncology-focused data points and more than 200 advanced machine learning algorithms, played a crucial role in accelerating LP-284's development timeline. This AI-driven approach represents a significant advancement in how biopharmaceutical companies can identify and develop promising oncology candidates more efficiently. The complete response in this heavily pretreated patient population suggests that LP-284 may offer new hope for patients who have failed conventional therapies, including the latest immunotherapies that have revolutionized cancer treatment but still leave some patients without effective options.

Lantern's presentation at the prestigious hematology congress underscores the scientific community's interest in novel approaches to treating aggressive lymphomas. The company highlighted partnership opportunities for expanding hematology portfolios, indicating potential for broader development and commercialization strategies. For more detailed information about the company's progress, investors can access updates through the company's newsroom at https://ibn.fm/LTRN. The successful application of artificial intelligence in identifying and developing this promising therapeutic candidate marks an important milestone in the convergence of technology and pharmaceutical development, potentially setting new standards for efficiency in oncology drug discovery.